Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIRPSA)

• Drug Name: Mitoglitazone Drug Info
• Synonyms: MSDC-0160; Mitoglitazone (TN)

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1] , [2]
Type-2 diabetes	5A11	Phase 2	[3]

• Cross-matching ID:
  PubChem CID: 10429242
  ChEBI ID: CHEBI:94409
  CAS Number: CAS 146062-49-9
  TTD Drug ID: DMIRPSA

Molecule-Related Drug Atlas

Drug(s) Targeting Insulin receptor (INSR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meglitinides	DM1OFHN	Type-2 diabetes	5A11	Approved	[5]
Human neutral insulin	DMA5OBU	Diabetic complication	5A2Y	Approved	[6]
Insulin Lyspro recombinant	DM5XHVR	Diabetic complication	5A2Y	Approved	[6]
Insulin, porcine	DMO95XI	Diabetic complication	5A2Y	Approved	[7]
Insulin recombinant	DMYVP5G	Diabetic complication	5A2Y	Approved	[6]
Metformin arginine-hemisuccinimide	DMTPAM3	Type-2 diabetes	5A11	Approved	[8]
Insulin-lispro	DM4O90W	Diabetic complication	5A2Y	Approved	[9]
Insulin-glulisine	DMQI0FU	Diabetic complication	5A2Y	Approved	[10]
Ryzodeq	DMOFP18	Type-2 diabetes	5A11	Approved	[11]
NN5401	DM0QV27	Diabetic complication	5A2Y	Phase 3	[11]

Drug(s) Targeting Mitochondrial protein unspecific (MP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epicatechin	DMN0EMP	Duchenne dystrophy	8C70	Phase 1/2	[1]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Insulin receptor (INSR)	TTCBFJO	INSR_HUMAN	Modulator	[4]
Mitochondrial protein unspecific (MP)	TTSJH2W	NOUNIPROTAC	Modulator	[1] , [2]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT01103414) Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients. U.S. National Institutes of Health.
• [4] An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease. Curr Alzheimer Res. 2014;11(6):564-73.
• [5] New drugs for type 2 diabetes mellitus: what is their place in therapy Drugs. 2008;68(15):2131-62.
• [6] Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
• [7] Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem. 2002 Jun;131(6):855-9.
• [8] Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol. 2004 Jun 1;67(11):2081-91.
• [9] Hope for insulin mimetic oral antidiabetic drugs. Eur J Endocrinol. 1999 Dec;141(6):561-2.
• [10] Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009;69(8):1035-57.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).